$3.54 Million in Sales Expected for Spero Therapeutics Inc (NASDAQ:SPRO) This Quarter

Wall Street brokerages expect Spero Therapeutics Inc (NASDAQ:SPRO) to announce sales of $3.54 million for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Spero Therapeutics’ earnings. The highest sales estimate is $5.37 million and the lowest is $2.00 million. Spero Therapeutics posted sales of $1.69 million in the same quarter last year, which suggests a positive year over year growth rate of 109.5%. The business is expected to announce its next quarterly earnings report on Thursday, March 12th.

According to Zacks, analysts expect that Spero Therapeutics will report full year sales of $18.06 million for the current fiscal year, with estimates ranging from $16.50 million to $19.89 million. For the next fiscal year, analysts anticipate that the firm will post sales of $14.12 million, with estimates ranging from $8.40 million to $19.25 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Spero Therapeutics.

A number of analysts have recently issued reports on the company. Cowen reaffirmed a “buy” rating on shares of Spero Therapeutics in a research report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Spero Therapeutics in a research report on Tuesday, January 21st. Finally, ValuEngine raised Spero Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $23.50.

SPRO opened at $8.99 on Friday. Spero Therapeutics has a 12-month low of $8.74 and a 12-month high of $14.48. The stock has a market cap of $184.74 million, a price-to-earnings ratio of -3.48 and a beta of 1.98. The business has a 50 day moving average of $9.52 and a 200-day moving average of $10.38. The company has a quick ratio of 6.90, a current ratio of 6.90 and a debt-to-equity ratio of 0.04.

A number of large investors have recently added to or reduced their stakes in SPRO. Marshall Wace LLP acquired a new stake in Spero Therapeutics during the 1st quarter worth approximately $39,000. Russell Investments Group Ltd. acquired a new stake in Spero Therapeutics during the 4th quarter worth approximately $55,000. Barclays PLC lifted its holdings in Spero Therapeutics by 106.3% during the 4th quarter. Barclays PLC now owns 11,361 shares of the company’s stock worth $109,000 after purchasing an additional 5,853 shares during the last quarter. D.A. Davidson & CO. lifted its holdings in Spero Therapeutics by 20.0% during the 3rd quarter. D.A. Davidson & CO. now owns 12,000 shares of the company’s stock worth $127,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Janney Montgomery Scott LLC acquired a new stake in Spero Therapeutics during the 4th quarter worth approximately $130,000. 48.43% of the stock is owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Recommended Story: What is a balanced fund?

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply